Effects of Probiotics in Patients With Ulcerative Colitis

This study has been terminated.
(Low recruitment)
Sponsor:
Collaborator:
Wakunaga Pharmaceutical Co., Ltd.
Information provided by:
University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00578799
First received: December 18, 2007
Last updated: July 1, 2009
Last verified: July 2009
  Purpose

This study is being conducted in patients who have been diagnosed with ulcerative colitis (UC), a form of inflammatory bowel disease (IBD) - a disease of the intestine.

The purpose of this study is to test the therapeutic (medical treatment) effects of daily consumption of Kyo-Dophilus (a commercially available dietary supplement often used by individuals with inflammatory bowel disease) on their UC. Kyo-Dophilus consists of three probiotic bacteria (beneficial bacteria to help maintain the balance of good bacteria in the intestine) to help treat inflammatory bowel disease caused by bad bacteria. Patients will still be maintained on their clinical standard of care for their UC as part of their participation in this study.


Condition Intervention Phase
Ulcerative Colitis
Dietary Supplement: Kyo-Dophilus
Dietary Supplement: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Probiotics in Patients With Ulcerative Colitis.

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • The UCDAI (Ulcerative Colitis Disease Activity Index) scores will be used to measure disease remission [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Results of patient questionnaires. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Histopathological scoring of disease activity [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: July 2008
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Kyo-Dophilus
Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
Dietary Supplement: Kyo-Dophilus
5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
Placebo Comparator: Placebo
placebo capsules (potato starch)
Dietary Supplement: placebo
placebo capsules (potato starch

Detailed Description:

Probiotics are defined as "live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host." Most probiotics are lactic acid producing bacteria that are endogenous to the human GI (gastrointestinal) tract and are commonly utilized in the fermentation of food products, such as yogurt. Disturbances in the composition of the bacterial flora of the GI tract are associated with diarrhea and inflammatory bowel disease (IBD), and consumption of some strains of probiotic bacteria are very effective for treating diarrhea and possibly individuals with ulcerative colitis (UC). We will test the effects of 3 strains of probiotic bacteria on UC. In addition to standard medical care for UC, participants will consume a dietary supplement of 3 probiotic bacteria (Kyo-Dophilus; Lacobacillus acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum) for 6 weeks. Changes in clinical symptoms and physiological markers of systemic and GI inflammation in subjects with UC will be assessed. Significant effects of the probiotics will be determined by comparing pre- and post-probiotic treatment measures for disease severity and level of inflammation and by comparing the probiotic treated group with the placebo treated control group. Any placebo effect on UC will also be assessed.

Forty subjects with ulcerative colitis will be recruited for the study and be provided a dietary supplement (5x109 bacteria/capsule, twice a day) for 6 weeks to 1/2 of the subjects and 1/2 of the UC subjects will be given a placebo control (potato starch). Standard medical care and therapies will be continued throughout the study. Initially, the physician will complete the Ulcerative Colitis Disease Activity Index (UCDAI) and the participants will complete the Shortened Inflammatory Bowel Disease Questionnaire (SIBDQ), and biopsies collected for histopathological assessment and analysis of inflammatory cytokine production (mRNA). Also, 30 ml of venous blood will be collected from each subject for analysis of serum/plasma levels of inflammatory cytokines and stress hormones. Subjects will be randomly assigned to the probiotic or placebo group (blinded to the physicians). After consuming the dietary supplement or placebo for 6 weeks, subjects will complete the SIBDQ questionnaire, the physician complete the UCDAI, be examined by sigmoidoscopy and tissue biopsies and blood samples collected. Also, during the 6 weeks of treatment, subjects will maintain a daily diary of their bowel habits. Data analysis will determine whether, relative to placebo controls, consumption of probiotics reduces the symptoms and levels of intestinal inflammation in patients with ulcerative colitis.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • We will be studying patients with mild to moderate active ulcerative colitis (UC).
  • Patients are eligible to participate if:

    • they are between 18 and 65 yr of age;
    • have an endoscopic and histologic confirmed diagnosis of UC for at least 1 yr; and
    • have at least a 2 week history of active UC that has not responded to mesalamine therapy.
  • Subjects will not have consumed any fermented products, such as yogurt, for at least 6 weeks prior to being entered into the trial.

Exclusion Criteria:

  • Subjects will be excluded if they have the following:

    • Crohn's disease,
    • disease less than 25 cm from the anal canal,
    • active enteric infection,
    • evidence of severe disease characterized by hemoglobin <8.0 g/dl, white blood cell count >20,000 cells/mm3, temperature >38.5◦C, albumin <25 g/dl, active disease >2 months, UCDAI < 2 or >9,
    • history of dysplasia of the colon or any cancer within 5 years,
    • clinically significant hematologic values (see above) or biochemical values (serum creatinine concentrations >1.5 times the upper limit of normal or alkaline phosphatase, aspartate aminotransferase, or alanine aminotransferase concentrations >2.5 times the upper limit of normal) are also ineligible.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00578799

Locations
United States, California
University of California, Irvine, Health Sciences Medical Center
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine
Wakunaga Pharmaceutical Co., Ltd.
Investigators
Principal Investigator: Dwight M Nance, Ph.D University of California, Irvine
  More Information

No publications provided

Responsible Party: Dwight M. Nance, Ph.D / Professor, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00578799     History of Changes
Other Study ID Numbers: OCRT07053, HS# 2007-6028
Study First Received: December 18, 2007
Last Updated: July 1, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Irvine:
ulcerative colitis

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 20, 2014